Celtic Pharma

Celtic Pharma is a private equity firm that specialized in the pharmaceutical and biotechnology sectors, operating with a virtual development model. Founded in 2004, the company focused on acquiring late-stage drug candidates and managing their clinical progression toward regulatory approval. By outsourcing research and development tasks to contract organizations, Celtic Pharma maintained a low-overhead structure while aggressively advancing its portfolio. Notable assets managed by the firm included Xerecept for peritumoral brain edema and royalty interests in the blockbuster drug Taltz. The firm played a significant role in pioneering the use of private equity capital for direct drug development and commercialization.